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Tuberculosis Immune Reconstitution Inflammatory 
Syndrome (TB-IRIS) in HIV co-infected TB patients is 
an intriguing but frequently occurring phenomenon 
experienced by patients after initiating anti retroviral 
therapy. It is characterized by paradoxical worsening 
of clinical and radiological manifestations of TB, after 
initiation of highly active antiretroviral therapy, when 
improvement in the general condition of the patient is 
usually anticipated. This paradoxical reaction is 
brought about by a cascade of inflammatory reactions 
triggered by the recovery of the immune system both 
in quality and quantity. Manifestations of TB-IRIS 
range from mild self-limiting symptoms to life threat-
ening compressive syndromes that could rarely be  
fatal. Often, this condition is confused with treatment 
failure or drug toxicity, which could lead to unneces-
sary drug interruption or substitution. Recognition of 
this syndrome assumes significance in the context of 
these two diseases, which mandate prolonged therapy 
with very high adherence to achieve the desired results. 
This article provides an overview of the risk factors, 
pathogenesis, clinical presentation, available diagnostic 
tools and treatment strategies for TB-IRIS with impli-
cations for patients and personnel involved in TB/HIV 
care. 
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Introduction 
TUBERCULOSIS Immune Reconstitution Inflammatory 
Syndrome (TB-IRIS) or paradoxical reaction is a phe-
nomenon that frequently complicates the management of 
HIV–TB co-infected persons. It is characterized by an ini-
tial improvement with anti-tuberculosis treatment (ATT), 
followed by a paradoxical worsening after initiation of 
antiretroviral treatment (ART), despite effective virologi-
cal suppression and control of both infections. With cur-
rent scientific evidence favouring the initiation of ART as 
early as possible in HIV–TB co-infected patients on ATT, 
the prevalence is likely to increase further1. TB-IRIS  
accounts for at least one third of all IRIS events in HIV-
infected patients in countries with a high prevalence of 
TB, with the frequency of occurrence and severity in-
creasing with immunosuppression2,3. The HTPN052 trial 
was aimed at studying the advantages of starting highly 
active antiretroviral therapy (HAART) in HIV-infected 
patients at a higher CD4 cell count (500 cells/mm3); this 
could serve as an effective prevention strategy not only 
against occurrence of opportunistic infections but IRIS as 
well4. TB patients initiated on ART, when CD4 cell count 
is relatively high, have a better outcome with lower pro-
bability of drug toxicity and IRIS incidence when com-
pared to patients with lower CD4 cell count at ART 
initiation5,6. Hence, the current National AIDS Control 
Organisation (NACO) guidelines emphasize the need for 
early ART initiation in all HIV/TB patients, irrespective 
of their CD4 cell count7. However, the reality is that HIV 
infection, in its early stages is usually cryptic producing 
non-specific symptoms. The diagnosis of HIV is often 
coupled with TB, the commonest opportunistic infection 
in India among HIV-infected individuals8. Trials con-
ducted at the National Institute for Research in Tubercu-
losis (NIRT), Chennai, have shown that approximately 
two-thirds of HIV–TB co-infected patients at the time of 
enrollment are in WHO stage IV, with an already deple-
ted CD4 cell count below 200 cells/mm3 (refs 9 and 10). 
A study from Pune showed that CD4 count was consid-
erably lower in patients, who presented themselves with 
combined pulmonary and extra pulmonary TB, compared 
to patients with TB confined to the lungs11. 
 TB-IRIS is of two types: (a) paradoxical TB-IRIS that 
occurs in patients started on ATT and subsequently 
started on ART and (b) unmasking TB-IRIS or ART  
associated TB that occurs in seemingly asymptomatic  
individuals, who are initiated on ART without a prior  
diagnosis of TB3. Management of both these conditions 
differs widely. In this review, we confine ourselves to a 
detailed description of the paradoxical type of TB-IRIS 
and highlight the important aspects of TB-IRIS including, 
possible risk factors, clinical features, diagnosis, clinical 
conditions that simulate IRIS and management. IRIS 
management requires expertise and if not detected early, 
could lead to increased morbidity and mortality, incurring *For correspondence. (e-mail: soumyas@trcchennai.in) 
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Table 1. Incidence of TB-IRIS in HIV–TB co-infection in various cohorts 
       Median  
        time Median 
       from  TB time from  
    Median Median Median diagnosis/ start of 
 Design of  Incidence age of CD4 at VL in at treatment ART to 
Study the study and type of  of TB- patients baseline baseline to IRIS IRIS 
investigator/year  TB in the cohort Year studied IRIS (%) (years) (cells/mm3) (log10/ml) in days in days 
 
Narita et al.12,  Prospective cohort, 1996–1997 12/33 (36%) 40* 51* 5.8 109 15 
 1998   culture proved TB,  
  including Rif resistant TB 
Breton et al.29,  Retrospective cohort,  1996–2001 16/37 (43%) 35 100 5.36 48 12 
 2004  clinical, radiological TB;  
  smear and culture positive TB  
Breen et al.15,  Retrospective study,  1997–2002 14/50 (35%) 36 NA NA 33 11 
 2004  bacteriological and  
   histological evidence of TB  
Kumaraswamy et al.16,  Retrospective cohort,  2000–2003 11/144 (8%) 29 123 NA 42 22 
 2004  clinical, radiological TB;  
   smear and culture  
  positive TB 
Manosuthi et al.57, Retrospective cohort,  2003–2004 21/167 (21%) 36 36 5.63 98 32 
 2006  clinical, radiological TB;  
   smear and culture positive TB 
Lawn et al.17,  Newly diagnosed TB and 2002–2005 19/160 (13%) 35 68 4..84 105 14 
 2007  patients on ATT 
Worodria et al.58, Prospective cohort  2007–2009 53/376 (21%) 35 52 NA 58 14 
 2012  bacteriological, clinical,  
   radiological TB  
Narendran et al.14, Prospective cohort of  2009– 65/180 (36%) 42 85 5.2 32 9 
 ongoing  culture positive rifampicin 
  sensitive pulmonary TB 
 
 
large costs to the health system by increased utilization of 
tertiary care facilities. 
 Prompt institution of anti-inflammatory drugs, usually 
corticosteroids, drastically alleviates the symptoms and 
signs, whereas unrecognized IRIS proves detrimental to 
patients. Non-adherence could occur due to drug phobia, 
brought about by initiation of ART, that could result in 
emergence of ATT and/or ART drug-resistant strains and 
an increased risk of developing treatment failure3. 
Increasing IRIS incidence 
Paradoxical IRIS is easier to recognize than the unmask-
ing type, because it follows a biphasic pattern of presen-
tation; an initial phase of improvement with ATT 
followed by ‘paradoxical’ deterioration after ART initia-
tion. This occurs despite effective virological suppression 
and in most cases, is associated with good immune re-
covery. Before the HIV era, reports of paradoxical reac-
tions or IRIS were confined to specific types of TB such 
as tuberculoma of the brain and peripheral lymphade-
nopathy12. Radiological worsening in pulmonary TB, 
with or without worsening of symptoms or ‘cryptic IRIS’, 
was reported in studies of TB chemotherapy in the pre-
HIV era13. However, the incidence of TB-IRIS doubled 
with the advent of HIV and further increased with earlier 
ART initiation12,14. A comparison of three groups of 
HIV–TB patients enrolled in three separate clinical trials 
had an incidence of 2%, 21%, 36% when ART was 
started (a) after completion of ATT, (b) after 2 months of 
ATT and (c) within the first 2 months of ATT respec-
tively9,10,14. Table 1 gives a detailed description of the 
baseline characteristics of HIV–TB patients enrolled in 
various studies from around the globe with data on timing 
of ART, immune status and the corresponding incidence 
of paradoxical TB-IRIS. A constant finding in all these 
studies is the higher incidence of IRIS when the interval 
between ATT and ART is shorter12,14–16. 
Risk factors for TB-IRIS – who is vulnerable  
and what predisposes to IRIS?  
IRIS occurs with greater severity and increased frequency 
in patients with disseminated TB or pulmonary TB with 
an occult/overt extra-pulmonary focus, in whom, a severe 
depletion of CD4 cell count is an associated feature. 
Presence of other opportunistic infections in addition to 
TB increases the risk. The increased antigenic load con-
tributed by extensive disease and multiple sites of  
involvement with a higher viral load at baseline is the 
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major predisposing factor for IRIS3,6,7,17. Studies reveal 
that the rapidity of viral load decline, rather than the pro-
portionate increase in absolute number of CD4 cells is the 
prime culprit, leading to unimpeded release of inflamma-
tory mediators contributing to IRIS occurrence18. The risk 
factors and sequence of events leading to IRIS occurrence 
are shown in Figure 1. To evaluate baseline differences 
and search for predictive markers between patients who 
experienced IRIS (IRIS cases) and those who remained 
asymptomatic (non-IRIS) a cohort of HIV-positive  
patients with culture confirmed pulmonary TB was pro-
spectively followed. Results showed evidence of more 
advanced stages of the disease and shorter time to ART 
among patients who developed IRIS compared to those 
who did not19 (Table 2). 
Pathogenesis of TB-IRIS: how and why does it 
occur? The influence of functional restoration of 
immune-competent cells  
An enigmatic fact is that certain patients have a signifi-
cant increase in CD4 cell count without experiencing 
IRIS while others exhibit symptoms and signs of IRIS 
without a corresponding increase in CD4 cell count. Pre-
liminary work on IRIS suggested that it occurred due to 
an increase in the number of CD4 cells after ART, which 
induced an exaggerated Th1 type of immune response12. 
However, it is not uncommon for IRIS to present within 
the first two weeks of starting ART when there is no  
demonstratable increase in the number of circulating CD4 
cells18. The explanation lies in the fact that the increase in 
CD4 cell count occurs in a bimodal fashion. The initial 
phase consists of a rapid increase in circulating cells rep-
resenting a redistribution of activated CD45RO memory 
cells, followed by a slow and steady expansion of naïve 
CD45RA cells when thymic function is restored that  
accounts for the sustained rise in CD4 cell count18. The 
majority of paradoxical IRIS cases occur within the first 
three months after starting ART due to the increase in 
CD45RO memory cells. Redistribution of these cells 
augments antigen specific responses, as they gain access 
to the site of infection, triggering an inflammatory cas-
cade19. Functional restoration of the immune system has a 
bigger role to play in IRIS pathogenesis than a mere in-
crease in numbers3,18,20. 
Cytokine storm and exaggerated Th-1  
response – ‘the ammunition in IRIS’ 
IRIS occurs due to an exaggerated TB-specific Th-1 re-
sponse to mycobacterial antigens as a result of immune 
restoration20. Bourgarit et al.21 showed that the un-
opposed PPD-specific Th-1 response with minimal Th2  
activity leads to acute release of pro-inflammatory cyto-
kines, resulting in IRIS. Increased interleukin-7 (IL-7) 
signaling in T cells, owing to the lack of competition for 
this cytokine in driving homeostatic proliferation of T 
cells in lymphopenia, has also been implicated22. The 
probable cytokines that contribute to the inflammation 
along with the risk factors have been shown in Figure 2. 
Tadokera et al.23 confirmed that the cytokine storm was 
indeed the preceding event, by not only demonstrating the 
increased levels of cytokines at symptom presentation, 
but showing the decrease when steroids were adminis-
tered. Sereti et al.24 showed that circulating T-cells pro-
duced increased interferon-gamma in response to 
antigenic stimulation of CD4 cells in vitro (that was 
demonstrated using enzyme linked immunospot assay or 
whole blood IFN-gamma release assays (IGRAs) and 
flow cytometric analysis of intracellular cytokine produc-
tion in activated T cells). Production of monocyte chemo-
tactic protein-1, that aids in chemotaxis of monocytes, 
was reduced in TB-IRIS patients, whereas interleukin-18 
a macrophage derived inducer of IFN-gamma and IFN-
gamma inducible protein (IP-10), which is chemotactic  
 
 
 
 
Figure 1. Flow chart depicting the risk factors and sequence of events 
leading to IRIS occurrence. IL, Interleukin; IFN-γ, interferon gamma; 
CRP, C-reactive protein; TNF-α, tumour necrosis factor alpha; MCP-1, 
monocyte chemotactic protein; IP-10, IFN-γ inducible protein; CD, 
cluster of differentiation; HB, hemoglobin; Th1, Type I helper T cell 
cytokines. 
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Table 2. Comparison of baseline characteristics between IRIS and non-IRIS among culture confirmed pulmo- 
  nary TB patients who were ATT and ART naïve at enrollment19 
Baseline characteristics (mean + SD)  IRIS (n = 25)  Non-IRIS (n = 22) 
 
Age (years)  37.7 ± 9.8  36.2 ± 7.2  
Weight (kg)  43.4 ± 8.8  42.7 ± 9.6  
Males (%) 76 81 
Hemoglobin (g%)*  8.7 ± 1.8  10.4 ± 1.9  
Hematocrit (%)**  25.5 ± 5.9  30.0 ± 5.7  
Viral load (log10) copies/ml***  5.8 ± 0.33  5.2 ± 0.91  
CD4 cell count (cells/mm3*) median (IQR) 93 (39–135)  156 (88–264)  
CD8 cell count (cells/mm3) median (IQR) 764 (311–1095)  459 (297–727)  
CD4/CD8 ratio*** median (IQR) 0.10 (0.05–0.18)  0.34 (0.21–0.47)  
Time to ART* (in days) median (IQR) 20 (14–30)  43 (23–68)  
*p < 0.05; **p < 0.01; ***p < 0.001. 
 
 
 
 
Figure 2. A, Chest skiagrams of a miliary TB patient showing radiological improvement with ATT and paradoxical worsening with ART and 
again clearance of opacities after steroids. a, PRE_ATT; b, PRE_ART (after 6 weeks of ATT); c, AT IRIS; d, AFTER STEROIDS. B, Diverse 
manifestations of IRIS in different patients. a, Massive right para tracheal lymphadenopathy with pleural effusion, presenting as stridor; b, Multiple 
tuberculoma brain; c, Cold abscess  mimicking a thyroid swelling; d, Enlarged peri-portal chain of lymph nodes. 
 
 
for effector T cells was increased in blood. This suggests 
that impaired clearance of mycobacterial antigenic load 
with augmented T-cell signalling and responses contrib-
ute to IRIS24. Another study of tuberculosis-associated 
IRIS in individuals infected with HIV found that whole-
blood cultures from patients with IRIS spontaneously 
(that is, without any sort of in vitro stimulation) produced 
increased levels of innate immune cell-derived cytokines 
and chemokines25. Our data from NIRT shows that inter-
leukin-6 and C-reactive protein are elevated in patients 
with IRIS both at baseline and at the time of IRIS, com-
pared to patients not experiencing IRIS, implicating their 
role as possible predictors of IRIS occurrence19. 
 On the contrary, Zaidi et al.26 demonstrated that the 
development of IRIS was not associated with differences 
in levels of T regulatory cells or baseline pro-inflamma-
tory cytokines. 
Diagnosis of IRIS and criteria used: tools that 
one can reasonably rely on 
Diagnosis of IRIS is still clinically based, supplemented 
by laboratory tests such as CD4 cell count and viral load. 
It is important for physicians to remember that the onset 
of this syndrome is chronologically linked to ART initia-
tion, substitution or interruption followed by re-initia-
tion3,27. A patient failing first line ART therapy may 
experience an IRIS episode after second line ART ther-
apy is initiated, when there is an effective decline in viral 
load6. The confirmatory feature favouring the diagnosis 
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Table 3. International network for the study of HIV-associated IRIS (INSHI) 
Consensus clinical case definition for paradoxical TB-IRIS (modified after Meintjes et.al.3) 
Case definition consists of three components  
(A) Antecedent requirements  
Both of the two following requirements must be met: 
• Diagnosis of tuberculosis: the tuberculosis diagnosis made before starting ART, fulfilling the WHO criteria for diagnosis of smear-
positive pulmonary tuberculosis, smear-negative pulmonary tuberculosis, or extra pulmonary tuberculosis 
• Initial response to tuberculosis treatment: the patient’s condition should have stabilized or improved on appropriate tuberculosis treat-
ment before ART initiation – e.g. cessation of night sweats, fevers, cough and weight loss. (Note: this does not apply to patients start-
ing ART within 2 weeks of starting tuberculosis treatment since insufficient time may have elapsed for a clinical response to be 
reported) 
(B) Clinical criteria 
The onset of tuberculosis-associated IRIS manifestations should be within 3 months of ART initiation, re-initiation or regimen change be-
cause of treatment failure. 
Of the following, at least one major criterion or two minor clinical criteria are required: 
Major criteria 
• New or enlarging lymph nodes, cold abscesses, or other focal tissue involvement – e.g. tuberculosis arthritis or tenosynovitis 
• New or worsening radiological features of tuberculosis (by chest radiography, abdominal and chest ultrasonography, CT or MRI) 
• New or worsening CNS tuberculosis (meningitis or focal neurological deficit due to space occupying lesions) 
• New or worsening serositis (pleural effusion, ascites or pericardial effusion) 
Minor criteria 
• New or worsening constitutional symptoms such as fever, night sweats or weight loss 
• New or worsening respiratory symptoms such as cough, breathlessness or compressive symptoms such as stridor or dysphagia 
• New or worsening abdominal pain accompanied by peritonitis, hepatomegaly, splenomegaly or abdominal adenopathy 
(C) Alternative explanations for clinical deterioration must be excluded if possible* 
• Failures; TB not responding to ATT due to drug resistant strains or virological failures with increasing viral load (where facilities are 
available) 
• Poor adherence to tuberculosis treatment 
• Another opportunistic infection or neoplasm (particularly when the initial diagnosis of TB has not been bacteriologically confirmed) 
• Adverse drug reaction to ATT or ART 
 
 
of paradoxical TB-IRIS is the bimodal pattern with initial 
improvement with ATT followed by recrudescence of 
symptoms (mimicking clinical deterioration) after start-
ing ART. Adherence to therapy needs to be ensured be-
fore establishing the diagnosis. In any case, routine work 
up of febrile episodes to rule out endemic infections like 
malaria, urinary tract infection, typhoid, etc. should be 
carried out. Radiological deterioration in chest skiagram 
is a usual accompaniment in most cases of IRIS, that oc-
curs with proven pulmonary TB14,19. Ultra sonogram of 
the abdomen and chest helps in localizing lesions in  
patients presenting with pyrexia of unknown origin 
(PUO). Computed tomography may be required in com-
plicated cases such as collapse of a lung segment or a 
lobe due to compression. Mediastinal mass lesion,  
empyema, abscesses, rib erosion, oseomyelitis and in-
trabdominal lesions that are not picked up by the ultra-
sonogram or the chest skiagram must be evaluated. 
Magnetic resonance imaging is useful in detecting lesions 
of the central nervous system as the location of the lesion 
determines the severity and type of manifestations that 
guides management. In patients who have adenopathy, 
serositis, etc., where a tissue/fluid specimen is available, 
it needs to be aspirated or biopsied and sent for bacterio-
logical staining in addition to Fine Needle Aspiration Cy-
tology or histopathology. Mycobacterium tuberculosis 
should be cultured where facilities exist, as smears can be 
positive, but the corresponding cultures are usually nega-
tive at IRIS. Dead or non-viable bacilli that are excreted 
during the intense inflammation result in the smear being 
positive. A negative mycobacterial culture, especially 
when the preexisting or baseline culture was positive and 
sensitive to first line drugs, helps to clinch the diagnosis. 
CD4 cell count and viral load estimation form the corner 
stone of laboratory evaluation for establishing the diag-
nosis with the latter taking precedence as CD4 cells may 
increase only after a lag period3,17,28. Concomitant  
decrease in plasma viremia is mandatory to demonstrate 
effective virological suppression to establish the diagno-
sis of IRIS beyond doubt and to differentiate from pro-
gression of HIV disease17. A decline of viral load less 
than 0.5 log10 copies/ml compared to baseline has a high 
negative predictive value in ruling out IRIS3,17,29.  
 Delayed hypersensitivity reaction using purified pro-
tein derivative (PPD), an in-vivo marker of T-cell acti-
vity, is also of value in proving IRIS. Patients who are 
PPD negative at start of ART become PPD positive at the 
time of IRIS17. Hypercalcemia is a strange accompani-
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ment of TB-IRIS caused by increased secretion of 1,25-
dihydroxy chole-calciferol by activated macrophages and 
CD4 T cells, that augments calcium absorption27. Among 
22 patients who were at risk for paradoxical TB-IRIS 
when starting ART in a South African study, a positive 
urinary LAM assay at baseline was observed in all five 
patients who developed TB-IRIS and in one among the 
remaining 17 patients who did not have TB-IRIS30. 
 The International Network Society for Study of HIV-
associated IRIS (INSHI) in 2008 came up with a practical 
definition that could be used in resource limited settings3 
(Table 3). Manosuthi et al.31 compared the French and the 
INSHI definitions and found a high concordance between 
the definitions with good sensitivity and specificity. A 
reasonable clause to include in the definition is the time 
interval from ART to IRIS, which is usually within three 
months, unless there is ART interruption followed by  
re-initiation. Retrospective evaluation of INSHI criteria 
among 333 IRIS patients showed INSHI definitions to be 
extremely useful in identification of IRIS32. 
Clinical features of TB-IRIS 
Manifestations of paradoxical IRIS are diverse (Figure 
2 A and B). The commonest and most consistent symptom 
is fever with rigour or chills closely resembling malaria 
and the commonest sign is lymph node enlargement that  
occurs in 75% of cases with or without associated intra-
thoracic adenopathy (20%)3,6. Worsening of parenchymal 
infiltrates on the chest skiagram is the second commonest 
manifestation (Figure 2 A)10,12. Presentations may vary 
from mere superficial lymphadenopathy and subcutaneous 
abscesses to severe forms like acute respiratory distress 
syndrome (ARDS), meningitis, space-occupying lesions 
like tuberculomas and viscus perforation which can end  
fatally3,6,17. Compressive syndromes due to lymphadenopa-
thy may manifest as stridor due to tracheal narrowing or 
superior vena caval (SVC) syndrome due to compression 
of SVC by upper mediastinal group of nodes33. Serositis is 
also not infrequent10. The severity and diversity of symp-
toms and signs depend on the site of infection29. Patients 
with abdominal TB suffer from pain and diarrhoea. Other 
abdominal manifestations include hepato-splenomegaly, 
psoas abscesses, splenic micro abscesses, splenic rupture, 
epididymoorchitis, uretric compression and acute renal 
failure3,17. Occurrence of osteomyelitis, sub-cutaneous 
abscesses and thromboembolic episodes have been repor-
ted34. A NIRT study of HIV–TB patients showed that ra-
diographic deterioration was present in 40% and extra-
pulmonary manifestations in 60% of patients experienc-
ing paradoxical TB-IRIS. In the same study, patients with 
IRIS presented with lymph node enlargement in one 
third, 23% had pleural effusion and one patient had tu-
berculoma brain. None died due to IRIS10. Meintjes et 
al.34, reported 59% had abdominal symptoms, 56% of the 
patients had hepatomegaly, 9% had splenomegaly and 5% 
had peritonitis. Ultrasonogram of the abdomen detected 
enlarged lymph nodes in 75% of the patients. 
Differential diagnosis of IRIS: the ‘close relatives 
of IRIS’ that need exclusion 
Multi-drug resistant TB (MDR-TB) is the closest mimic 
to TB-IRIS34. HIV–TB co-infected individuals have a 
higher propensity for emergence of multidrug resistant 
TB than individuals with TB alone35. HIV enteropathy 
impairs absorption and diarrhea by entero-pathogenic  
organisms shortens the gastro-intestinal transit time lead-
ing to mal-absorption and sub-therapeutic dosing. A 
higher tissue burden of bacilli due to defective clearance 
imposed by immuno-deficiency coupled with a subopti-
mal dosage of ATT provides an ideal scenario for emer-
gence of drug-resistant mutants36–38. The initial bacterial 
population may decline as a result of drug-sensitive ba-
cilli succumbing to ATT, which is progressively replaced 
by drug-resistant mutants that rise in a couple of months. 
This phenomenon described by Toman as the ‘fall and 
rise phenomenon’ typically mimics the bimodal pattern of 
improvement followed by deterioration that occurs in 
IRIS39. A study of HIV–TB co-infected patients con-
ducted in the pre-HAART era showed a 10% incidence of 
rifampicin resistance when they failed ATT9. Meintjes et 
al.34 showed that 10% of their cohort who presented as 
TB-IRIS were actually MDR-TB cases. IRIS in MDR-TB 
is not a rarity and they are not mutually exclusive  
either40. Exclusion of MDR-TB is an absolute priority 
when use of steroids is contemplated. Steroids which re-
main the cornerstone of treatment could spell disaster in 
the scenario of MDR-TB, ending fatally. The program-
matic management of MDR-TB (PMDT) guidelines pro-
moting the use of rapid molecular tests to detect drug 
resistance in all HIV patients with TB, may help in diag-
nosing primary MDR-TB earlier, so that the two may be 
easily differentiated and managed accordingly41. 
 With the phase out of stavudine from the ART pro-
gramme, due to its side effects including lipodystrophy 
and dyslipaedemia, zidovudine based regimes have  
become the main stay of HIV management in India. Zido-
vudine-induced anemia also simulates IRIS, as it mimics 
the same symptoms as IRIS. The incidence of zidovu-
dine-induced anemia in an ongoing RCT showed a 7% 
incidence in HIV–TB with 3/4th of the patients present-
ing themselves with fever and rigour that settled after 
withdrawing zidovudine14. Patients with IRIS occurring 
after 3 months of ART initiation (late onset IRIS) need to 
be differentiated from ART failure and HIV progression 
by sequential estimation of viral load6,8. Viral load is 
usually undetectable in late onset IRIS. 
 Lymphoma of the non-Hodgkins type commonly affects 
HIV patients. This condition could flare up in HIV  
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patients after ART and may be misdiagnosed as TB-IRIS. 
Lymphoma and TB are known to co-exist. Hence, what 
appears as TB-IRIS of the lymph node may turn out to be 
‘unmasking IRIS’ of lymphoma42,43. Other important  
differential diagnoses include infection with non-
tuberculous mycobacteria especially Mycobacterium 
Avium Intracellulare, Pneumocystitis Cariini Pneumo-
niae, Cryptococcus and Nocardia. Nocardia being par-
tially acid fast, mimics TB not only in presentation such 
as serosal involvement and chest wall abscesses, but also 
in microscopic findings. 
Management 
Most HIV-infected patients in developing countries ap-
proach health care systems only when an opportunistic 
infection like TB occurs. They are usually at an advanced 
stage of immunodeficiency at presentation. Recent WHO 
guidelines recommend ART initiation at a higher CD4 
cell cut off of 500 cells/mm3, compared to the previous 
350 cells/mm3 (ref. 44). Haddow et al.45 demonstrated 
that the increase in CD4 cell count by 50 cells during 
ART initiation, the risk of experiencing IRIS was reduced 
by 17% (95% CI 6–26%), with a 43% reduction in all 
cause mortality. Therefore, earlier initiation of ART 
would lead to lower IRIS incidence in future. 
 An interesting fact is that long-term Cotrimaxozole 
therapy prior to ART reduced IRIS events compared to 
concurrently starting it with ART, probably by reducing 
the incidence of other opportunistic infections45. Meticu-
lous screening for opportunistic infections including TB 
prior to ART initiation would be the second preventive 
step against IRIS. This is especially so in countries ende-
mic for TB and cryptococcosis that are associated with 
significant morbidity and mortality. Detection of latent 
TB, extra-pulmonary TB and smear negative TB in HIV, 
especially in the setting of profound lymphopenia is chal-
lenging, but expanding access to more sensitive tools like 
Xpert MTB/rif and other rapid molecular tests, should 
help46. 
Optimal timing of ART in the context of  
TB–HIV co-infection 
One practical solution to the problem of IRIS occurrence 
is optimizing the time of ART initiation with respect to 
ATT. Physicians need to strike a balance between delay-
ing ART and its impact on survival, weighed against the 
odds of developing IRIS when ART is started early. The 
flexibility offered in the NACO guidelines to start  
patients on ART in HIV–TB co-infection within a span of 
2–8 weeks after ATT, may prove beneficial in tackling 
this problem7. Three major studies on timing of ART in 
HIV–TB co-infection have provided important insights in 
maximizing survival benefits while reducing the risk of 
IRIS. The SAPIT study (South African Starting Antiret-
roviral Therapy at Three Points in Tuberculosis Therapy) 
concluded that initiation of ART within the intensive 
phase was necessary to reduce mortality by half (56%) 
among HIV–TB co-infected patients on ATT compared to 
starting ART after 6 months (ATT completion)47. How-
ever, among patients starting ART within the first month 
of ATT, a three times higher incidence of IRIS and 90% 
more incidence of toxicity was documented, when com-
pared to those patients starting ART at the end of 2 
months, without any additional survival benefits48. ACTG 
5221 clinical trial enrolled 809 patients with a median 
CD4 cell count of 77 cells/mm3 and a median viral load 
of 5.4 log10 copies/ml. Unfavourable response (mortality 
or AIDS defining illness) was 12.6% in the early ART 
group versus 16.1% in the late ART group (p = 0.45). But 
the incidence of IRIS was reduced to half in the late ART 
group. Viral load suppression at the end of 48 weeks was 
equivalent in both the groups. The clear cut survival 
benefit of early ART initiation, within 2 weeks of starting 
ATT was evident only in the group that had a CD4 cell 
count < 50 cells/mm3 (ref. 49). 
 The CAMELIA study (Cambodian Early versus Late 
Introduction of Antiretrovirals) initiated ART among 
dually infected patients within two weeks of ATT in one 
group and between 8 and 12 weeks in the other group. 
Mortality was reduced in the former group. However, the 
overall median CD4 cell count of the study subjects  
enrolled in this Cambodian study, was only 25 cells/mm3, 
confirming the benefit of early ART in patients with  
advanced disease50. NIRT experience among HIV–TB 
dually infected subjects showed an overall mortality of 
14.7% when started at 2 months compared to 8.3% when 
it was initiated in the intensive phase (p = 0.07)10,14. 
However, the incidence of IRIS was 20% with later ART 
compared to 38% when started within the intensive phase 
(p = 0.01)14,19. The key message from the findings of the 
above studies, conducted in different settings, is that 
among patients with CD4 cell count of more than 50 
cells, deferral of ART after the first few weeks of ATT 
helped in reducing toxicity and IRIS without compromis-
ing on survival. There are however exceptions to this 
rule. Study by Torok et al.51 on tuberculous meningitis 
found that the immediate ART group had a higher inci-
dence of grade 4 adverse reactions and IRIS, compared to 
the delayed group that started ART at 2 months without 
an accompanying survival advantage. It should be  
emphasized that individualized therapy taking into ac-
count the stage of the disease and facilities available for 
tackling IRIS would serve as the best option. 
Treatment  
Paradoxical IRIS is usually associated with considerable 
morbidity and substantial utilization of tertiary care servi-
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ces, requiring appropriate experts to manage this syn-
drome effectively. Anti-inflammatory drugs form the 
backbone of the therapy, starting with non-steroidal anti-
inflammatory agents being the agents of first choice. 
Steroids, the principal therapy for IRIS management, 
have been used in more than a third of the case52. Manabe 
et al.18 reported 75% of patients experiencing IRIS re-
quired steroid therapy. A dose of 0.5–2 mg/kg body 
weight, tapered over a period of 4–8 weeks depending on 
the site and severity of the disease is usually recom-
mended3,18,52. Manifestations of IRIS such as aseptic 
meningitis, pericardial effusion, mediastinal adenopathy 
with compression, acute respiratory distress syndrome, 
etc. may require parenteral steroids like hydrocortisone, 
methyl prednisolone or dexamethasone to start with, fol-
lowed by switch to oral prednisolone. Deflazacort, a 
prodrug derivative of prednisolone, is a proven alterna-
tive in children with reduced suppression of the limbic 
system and interference of the circadian rhythm of  
endogenous steroid production. Its higher potency and 
greater safety profile with lower osteoporotic and dia-
betogenic potential makes it ideal for use in children,  
especially when long-term therapy is contemplated53. A 
double-blind study conducted in South Africa using three 
months of steroids and placebo in TB-IRIS showed a re-
duced duration of hospital stay, faster clinical improve-
ment and greater radiological improvement in the steroid 
group52. Side effects due to immunological suppression in 
the form of new infections were slightly more in the ster-
oid arm, but without appreciable morbidity. Thalidomide, 
another potent anti-inflammatory drug, has been used for 
refractory or relapsing IRIS cases and in patients who 
eventually become steroid dependent in order to wean 
them off steroids54. Anecdotal reports of pentoxifylline 
and monteleukast (a leukotriene inhibitor) used for the 
treatment of IRIS have been published, but routine use 
and benefits have not been explicitly determined55,56. The 
role of leukotriene pathways in the pathogenesis of IRIS 
need to be established before contemplating on routine 
use of leucotriene antagonists for treatment of TB-IRIS in 
clinical practice. Rarely, uncontrolled and life threatening 
IRIS cases need a temporary interruption of ART as a last 
resort, in addition to steroids3,12. The decision to withhold 
ART has to be carefully evaluated after meticulous  
efforts to prove it as precipitating IRIS, and other alterna-
tive diagnoses have been reasonably excluded. Patients 
need to be closely monitored in a tertiary care facility 
during the ‘ART-free’ period. 
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